Patents by Inventor Laura Lin
Laura Lin has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20240076386Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to E-selectin. The invention includes uses, and associated methods of using the antibodies, and antigen-binding fragments thereof.Type: ApplicationFiled: February 27, 2023Publication date: March 7, 2024Inventors: James Reasoner Apgar, Sheryl Rubio Bowley, Joanne Elizabeth-Ayriss Elwell, Laura Lin, Jatin Narula, Chuenlei Parng, Debra Denene Pittman, Swapnil Rakhe, Chihyi Vincent Yu
-
Patent number: 11597770Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to E-selectin. The invention includes uses, and associated methods of using the antibodies, and antigen-binding fragments thereof.Type: GrantFiled: January 21, 2021Date of Patent: March 7, 2023Assignee: Pfizer Inc.Inventors: James Reasoner Apgar, Sheryl Rubio Bowley, Joanne Elizabeth-Ayriss Elwell, Laura Lin, Jatin Narula, Chuenlei Parng, Debra Denene Pittman, Swapnil Rakhe, Chihyi Vincent Yu
-
Patent number: 11155610Abstract: The invention provides a dual VEGF/PDGF antagonist comprising a VEGF antagonist linked to a PDGF antagonist. The VEGF antagonist is an antibody to a VEGF or VEGFR or is a VEGFR extracellular trap segment (i.e., a segment from the extracellular region of one or more VEGFR receptors that inhibits binding of at least one VEGFR to at least one VEGF). The PDGF antagonist is an antibody to a PDGF or PDGFR or is a PDGFR extracellular trap segment (i.e., segment from the extracellular region of one or more PDGFRs, which inhibits binding of at least one PDGFR and at least one PDGF). The dual antagonist is preferably conjugated to a half-life extending moiety, such as a HEMA-PC polymer. The dual antagonist is particularly useful for treating wet aged related macular degeneration.Type: GrantFiled: November 21, 2017Date of Patent: October 26, 2021Assignee: KODIAK SCIENCES INC.Inventors: Daniel Victor Perlroth, Stephen A. Charles, James Aggen, Didier Benoit, Wayne To, Lidia Mosyak, Laura Lin, Justin Cohen, Tetsuya Ishino, William Somers
-
Publication number: 20210324028Abstract: The present invention relates to human interleukin 15 (IL-15) variants that have therapeutic and diagnostic use, and methods for making thereof. The present invention also provides fusion proteins comprising a human IL-15 variant. Also provided are methods of stimulating or suppressing immune responses in a mammal, and methods of treating a disorder (e.g., cancer) using the IL-15 variants or the fusion protein of such IL-15 variants.Type: ApplicationFiled: June 24, 2021Publication date: October 21, 2021Applicant: Pfizer Inc.Inventors: Yik Andy Yeung, Reid Martin Renny Feldman, Ling Hon Matthew Chu, Javier Fernando Chaparro Riggers, Ivana Djuretic, Laura Lin, Lidia Mosyak
-
Publication number: 20210246213Abstract: The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to E-selectin. The invention includes uses, and associated methods of using the antibodies, and antigen-binding fragments thereof.Type: ApplicationFiled: January 21, 2021Publication date: August 12, 2021Inventors: James Reasoner Apgar, Sheryl Rubio Bowley, Joanne Elizabeth-Ayriss Elwell, Laura Lin, Jatin Narula, Chuenlei Parng, Debra Denene Pittman, Swapnil Rakhe, Chihyi Vincent Yu
-
Patent number: 11059876Abstract: The present invention relates to human interleukin 15 (IL-15) variants that have therapeutic and diagnostic use, and methods for making thereof. The present invention also provides fusion proteins comprising a human IL-15 variant. Also provided are methods of stimulating or suppressing immune responses in a mammal, and methods of treating a disorder (e.g., cancer) using the IL-15 variants or the fusion protein of such IL-15 variants.Type: GrantFiled: February 26, 2019Date of Patent: July 13, 2021Assignee: PFIZER INC.Inventors: Yik Andy Yeung, Reid Martin Renny Feldman, Ling Hon Matthew Chu, Javier Fernando Chaparro Riggers, Ivana Djuretic, Laura Lin, Lidia Mosyak
-
Publication number: 20200392205Abstract: The present disclosure provides muteins of FVIII to which a biocompatible polymer may be attached to increase the circulatory half-life of the muteins, as well as conjugates of such muteins and biocompatible polymers.Type: ApplicationFiled: February 24, 2020Publication date: December 17, 2020Inventors: James Apgar, Debra Pittman, Mark Stahl, Laura Lin, Justin Cohen
-
Publication number: 20200262905Abstract: The invention provides a dual VEGF/PDGF antagonist comprising a VEGF antagonist linked to a PDGF antagonist. The VEGF antagonist is an antibody to a VEGF or VEGFR or is a VEGFR extracellular trap segment (i.e., a segment from the extracellular region of one or more VEGFR receptors that inhibits binding of at least one VEGFR to at least one VEGF). The PDGF antagonist is an antibody to a PDGF or PDGFR or is a PDGFR extracellular trap segment (i.e., segment from the extracellular region of one or more PDGFRs, which inhibits binding of at least one PDGFR and at least one PDGF). The dual antagonist is preferably conjugated to a half-life extending moiety, such as a HEMA-PC polymer. The dual antagonist is particularly useful for treating wet aged related macular degeneration.Type: ApplicationFiled: February 19, 2020Publication date: August 20, 2020Applicant: KODIAK SCIENCES INC.Inventors: D. Victor Perlroth, Stephen A. Charles, James Aggen, Didier Benoit, Wayne To, Lidia Mosyak, Laura Lin, Justin Cohen, Tetsuya Ishino, William Somers
-
Patent number: 10570189Abstract: The present disclosure provides muteins of FVIII to which a biocompatible polymer may be attached to increase the circulatory half-life of the muteins, as well as conjugates of such muteins and biocompatible polymers.Type: GrantFiled: March 4, 2015Date of Patent: February 25, 2020Assignee: PFIZER INC.Inventors: James Apgar, Debra Pittman, Mark Stahl, Laura Lin, Justin Cohen
-
Publication number: 20190263877Abstract: The present invention relates to human interleukin 15 (IL-15) variants that have therapeutic and diagnostic use, and methods for making thereof. The present invention also provides fusion proteins comprising a human IL-15 variant. Also provided are methods of stimulating or suppressing immune responses in a mammal, and methods of treating a disorder (e.g., cancer) using the IL-15 variants or the fusion protein of such IL-15 variants.Type: ApplicationFiled: February 26, 2019Publication date: August 29, 2019Applicant: Pfizer Inc.Inventors: Yik Andy Yeung, Reid Martin Renny Feldman, Ling Hon Matthew Chu, Javier Fernando Chaparro Riggers, Ivana Djuretic, Laura Lin, Lidia Mosyak
-
Publication number: 20180244762Abstract: The invention provides a dual VEGF/PDGF antagonist comprising a VEGF antagonist linked to a PDGF antagonist. The VEGF antagonist is an antibody to a VEGF or VEGFR or is a VEGFR extracellular trap segment (i.e., a segment from the extracellular region of one or more VEGFR receptors that inhibits binding of at least one VEGFR to at least one VEGF). The PDGF antagonist is an antibody to a PDGF or PDGFR or is a PDGFR extracellular trap segment (i.e., segment from the extracellular region of one or more PDGFRs, which inhibits binding of at least one PDGFR and at least one PDGF). The dual antagonist is preferably conjugated to a half-life extending moiety, such as a HEMA-PC polymer. The dual antagonist is particularly useful for treating wet aged related macular degeneration.Type: ApplicationFiled: November 21, 2017Publication date: August 30, 2018Applicant: KODIAK SCIENCES INC.Inventors: D. Victor Perlroth, Stephen A. Charles, James Aggen, Didier Benoit, Wayne To, Lidia Mosyak, Laura Lin, Justin Cohen, Tetsuya lshino, William Somers
-
Patent number: 9840553Abstract: The invention provides a dual VEGF/PDGF antagonist comprising a VEGF antagonist linked to a PDGF antagonist. The VEGF antagonist is an antibody to a VEGF or VEGFR or is a VEGFR extracellular trap segment (i.e., a segment from the extracellular region of one or more VEGFR receptors that inhibits binding of at least one VEGFR to at least one VEGF). The PDGF antagonist is an antibody to a PDGF or PDGFR or is a PDGFR extracellular trap segment (i.e., segment from the extracellular region of one or more PDGFRs, which inhibits binding of at least one PDGFR and at least one PDGF). The dual antagonist is preferably conjugated to a half-life extending moiety, such as a HEMA-PC polymer. The dual antagonist is particularly useful for treating wet aged related macular degeneration.Type: GrantFiled: June 29, 2015Date of Patent: December 12, 2017Assignee: KODIAK SCIENCES INC.Inventors: D. Victor Perlroth, Stephen A. Charles, James Aggen, Didler Benoit, Wayne To, Lidia Mosyak, Laura Lin, Justin Cohen, Tetsuya Ishino, William Somers
-
Publication number: 20150376271Abstract: The invention provides a dual VEGF/PDGF antagonist comprising a VEGF antagonist linked to a PDGF antagonist. The VEGF antagonist is an antibody to a VEGF or VEGFR or is a VEGFR extracellular trap segment (i.e., a segment from the extracellular region of one or more VEGFR receptors that inhibits binding of at least one VEGFR to at least one VEGF). The PDGF antagonist is an antibody to a PDGF or PDGFR or is a PDGFR extracellular trap segment (i.e., segment from the extracellular region of one or more PDGFRs, which inhibits binding of at least one PDGFR and at least one PDGF). The dual antagonist is preferably conjugated to a half-life extending moiety, such as a HEMA-PC polymer. The dual antagonist is particularly useful for treating wet aged related macular degeneration.Type: ApplicationFiled: June 29, 2015Publication date: December 31, 2015Applicant: OLIGASIS, LLCInventors: D. Victor Perlroth, Stephen A. Charles, James Aggen, Didier Benoit, Wayne To, Lidia Mosyak, Laura Lin, Justin Cohen, Tetsuya Ishino, William Somers
-
Publication number: 20150306234Abstract: The present disclosure provides muteins of FVIII to which a biocompatible polymer may be attached to increase the circulatory half-life of the muteins, as well as conjugates of such muteins and biocompatible polymers.Type: ApplicationFiled: March 4, 2015Publication date: October 29, 2015Inventors: James Apgar, Debra Pittman, Mark Stahl, Laura Lin, Justin Cohen
-
Patent number: 8473319Abstract: A system and method for encouraging the exchange of feedback in an enterprise. An example method includes providing one or more user interface controls for configuring a feedback reminder to automatically include predetermined insight pertaining to a potential participant in a future feedback exchange; sending the feedback reminder to a messaging system or application; providing a user option to view content of the feedback reminder; and displaying the feedback reminder in response to user selection of the first user option. Another user option enables selection of particular insight, derived from a talent management system, for inclusion in the feedback reminder. The messaging system may include an email application or an application for displaying a worklist.Type: GrantFiled: February 28, 2012Date of Patent: June 25, 2013Assignee: Oracle International CorporationInventors: Yumiko Christine Yokoi, Nancy V. Lang, Justin Craig Field, Andrew Philip Gillibrand, Steven K. Chu, Hong (Laura) Lin
-
Publication number: 20120303421Abstract: A system and method for encouraging the exchange of feedback in an enterprise. An example method includes providing one or more user interface controls for configuring a feedback reminder to automatically include predetermined insight pertaining to a potential participant in a future feedback exchange; sending the feedback reminder to a messaging system or application; providing a user option to view content of the feedback reminder; and displaying the feedback reminder in response to user selection of the first user option. Another user option enables selection of particular insight, derived from a talent management system, for inclusion in the feedback reminder. The messaging system may include an email application or an application for displaying a worklist.Type: ApplicationFiled: February 28, 2012Publication date: November 29, 2012Applicant: Oracle International CorporationInventors: Yumiko Christine Yokoi, Nancy V. Lang, Justin Craig Field, Andrew Philip Gillibrand, Steven K. Chu, Hong (Laura) Lin
-
Patent number: 7584087Abstract: A three-dimensional structure of human protein kinase C theta (PKC?) can be used in methods of designing an agent that interacts with PKC?. The agent can be an inhibitor of PKC? activity.Type: GrantFiled: April 6, 2005Date of Patent: September 1, 2009Assignee: WyethInventors: Zhang Bao Xu, Stephane Olland, Scott Wolfrom, Karl Malakian, Laura Lin, Mark Stahl, Julie Lee, Lori Fitz, Rita Greco, Divya Chaudhary, William Stuart Somers, Lidia Mosyak
-
Publication number: 20090136111Abstract: A system and method of diagnosing a medical condition in a patient from accessing image data and non-image data of a patient, analyzing the combination of image data and non-image data to generate an output with image findings and a risk assessment for diagnosing certain medical conditions in the patient. The image data may be acquired from an image acquisition system. The non-image data may include clinical data of the patient and may be acquired from a user interface, an electronic medical record, and/or findings from an expert system from previous imaging sessions.Type: ApplicationFiled: November 25, 2007Publication date: May 28, 2009Applicant: GENERAL ELECTRIC COMPANYInventors: Kadri Nizar Jabri, Renuka Uppaluri, Yan Laura Lin, Huanzhong Li, Gopal Biligeri Avinash, John Michael Sabol
-
Publication number: 20070048785Abstract: Anti-IL-13 antibodies, crystals of anti-IL-13 antibodies, IL-13 polypeptide/anti-IL-13 antibody complexes, crystals of IL-13 polypeptide/anti-IL-13 antibody complexes, IL-13R?1 polypeptide/IL-13 polypeptide/anti-IL-13 antibody complexes, crystals of IL-13R?1 polypeptide/IL-13 polypeptide/anti-IL-13 antibody complexes, and related methods and software systems are disclosed.Type: ApplicationFiled: June 9, 2005Publication date: March 1, 2007Inventors: Laura Lin, Kevin Parris, Amy Sze Tam, Xiang-Yang Tan, Tania Shane, John Dumas, James Wilhelm, Mark Stahl, Lidia Mosyak, Zhixiang Hu
-
Publication number: 20060063228Abstract: This application relates to antibodies, e.g., humanized antibodies, and antigen-binding fragments thereof, that bind to interleukin-13 (IL-13), in particular, human IL-13, and their uses in regulating immune responses mediated by IL-13. The antibodies disclosed herein are useful in diagnosing, preventing, and/or treating a subject, e.g., a human patient, one or more IL-13-associated disorders, e.g., respiratory disorders (e.g., asthma); atopic disorders (e.g., allergic rhinitis); inflammatory and/or autoimmune conditions of the skin (e.g., atopic dermatitis), and gastrointestinal organs (e.g., inflammatory bowel diseases (IBD)), as well as fibrotic and cancerous disorders.Type: ApplicationFiled: June 9, 2005Publication date: March 23, 2006Inventors: Marion Kasaian, Lioudmila Tchistiakova, Geertruida Veldman, Kimberly Marquette, Xiang-Yang Tan, Debra Donaldson, Laura Lin, Tania Shane, Amy Tam, Eric Feyfant, Nancy Wood, Lori Fitz, Angela Widom, Kevin Parris, Samuel Goldman, Jose Saldanha